124 related articles for article (PubMed ID: 33075795)
1. Efficacy of a Novel Second-Generation Somatostatin-Dopamine Chimera (TBR-065) in Human Medullary Thyroid Cancer: A Preclinical Study.
Dicitore A; Cantone MC; Gaudenzi G; Saronni D; Carra S; Borghi MO; Albertelli M; Ferone D; Hofland LJ; Persani L; Vitale G
Neuroendocrinology; 2021; 111(10):937-950. PubMed ID: 33075795
[TBL] [Abstract][Full Text] [Related]
2. Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.
Carra S; Gaudenzi G; Dicitore A; Saronni D; Cantone MC; Plebani A; Ghilardi A; Borghi MO; Hofland LJ; Persani L; Vitale G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809722
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies.
Vitale G; Lupoli G; Guarrasi R; Colao A; Dicitore A; Gaudenzi G; Misso G; Castellano M; Addeo R; Facchini G; Del Prete S; Caraglia M
J Clin Endocrinol Metab; 2013 Oct; 98(10):E1567-74. PubMed ID: 23884781
[TBL] [Abstract][Full Text] [Related]
4. The cAMP analogs have potent anti-proliferative effects on medullary thyroid cancer cell lines.
Dicitore A; Grassi ES; Caraglia M; Borghi MO; Gaudenzi G; Hofland LJ; Persani L; Vitale G
Endocrine; 2016 Jan; 51(1):101-12. PubMed ID: 25863490
[TBL] [Abstract][Full Text] [Related]
5. Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion.
Giardino E; Catalano R; Mangili F; Barbieri AM; Treppiedi D; Elli FM; Dolci A; Contarino A; Spada A; Arosio M; Mantovani G; Peverelli E
Mol Cell Endocrinol; 2021 Jan; 520():111092. PubMed ID: 33248230
[TBL] [Abstract][Full Text] [Related]
6. Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells.
Klubo-Gwiezdzinska J; Jensen K; Costello J; Patel A; Hoperia V; Bauer A; Burman KD; Wartofsky L; Vasko V
Endocr Relat Cancer; 2012 Jun; 19(3):447-56. PubMed ID: 22389381
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of somatostatin analogues in rat GH-secreting pituitary tumor cell lines.
Dicitore A; Saronni D; Gaudenzi G; Carra S; Cantone MC; Borghi MO; Persani L; Vitale G
J Endocrinol Invest; 2022 Jan; 45(1):29-41. PubMed ID: 34128215
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT.
Zatelli MC; Tagliati F; Taylor JE; Piccin D; Culler MD; degli Uberti EC
Horm Metab Res; 2002 May; 34(5):229-33. PubMed ID: 12063634
[TBL] [Abstract][Full Text] [Related]
9. Antineoplastic Activity of an Old Natural Antidiabetic Biguanide on the Human Thyroid Carcinoma Cell Line.
Nozhat Z; Zarkesh M; Baldini E; Mohammadi-Yeganeh S; Azizi F; Hedayati M
Anticancer Agents Med Chem; 2022; 22(4):713-720. PubMed ID: 33461474
[TBL] [Abstract][Full Text] [Related]
10. TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice.
Halem HA; Hochgeschwender U; Rih JK; Nelson R; Johnson GA; Thiagalingam A; Culler MD
Endocrinology; 2020 Aug; 161(8):. PubMed ID: 32591776
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells.
Cuny T; Graillon T; Defilles C; Datta R; Zhang S; Figarella-Branger D; Dufour H; Mougel G; Brue T; Landsman T; Halem HA; Culler MD; Barlier A; Saveanu A
Pituitary; 2021 Jun; 24(3):351-358. PubMed ID: 33433890
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells.
Bertazza L; Barollo S; Radu CM; Cavedon E; Simioni P; Faggian D; Plebani M; Pelizzo MR; Rubin B; Boscaro M; Pezzani R; Mian C
J Cell Mol Med; 2015 Sep; 19(9):2244-52. PubMed ID: 26081844
[TBL] [Abstract][Full Text] [Related]
13. Recurrent Metastatic Medullary Thyroid Carcinoma: A Case of Sustained Response to Prolonged Treatment with Somatostatin Analogues.
Cano JM; Galán R; López R
Thyroid; 2017 Nov; 27(11):1450-1455. PubMed ID: 28927353
[TBL] [Abstract][Full Text] [Related]
14. Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.
Zatelli MC; Piccin D; Tagliati F; Bottoni A; Luchin A; Vignali C; Margutti A; Bondanelli M; Pansini GC; Pelizzo MR; Culler MD; Degli Uberti EC
J Clin Endocrinol Metab; 2006 Jun; 91(6):2218-24. PubMed ID: 16569735
[TBL] [Abstract][Full Text] [Related]
15. Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice.
Starenki D; Singh NK; Jensen DR; Peterson FC; Park JI
Cancer Lett; 2013 Oct; 339(1):144-51. PubMed ID: 23856028
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer.
Saronni D; Gaudenzi G; Dicitore A; Carra S; Cantone MC; Borghi MO; Barbieri A; Mignani L; Hofland LJ; Persani L; Vitale G
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139603
[TBL] [Abstract][Full Text] [Related]
17. Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line.
Tuccilli C; Baldini E; Prinzi N; Morrone S; Sorrenti S; Filippini A; Catania A; Alessandrini S; Rendina R; Coccaro C; D'Armiento M; Ulisse S
Endocrine; 2016 May; 52(2):287-95. PubMed ID: 26215279
[TBL] [Abstract][Full Text] [Related]
18. Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro.
Ferrari SM; Fallahi P; La Motta C; Bocci G; Corrado A; Materazzi G; Galleri D; Piaggi S; Danesi R; Da Settimo F; Miccoli P; Antonelli A
Surgery; 2014 Nov; 156(5):1167-76. PubMed ID: 25151558
[TBL] [Abstract][Full Text] [Related]
19. Thiocoraline alters neuroendocrine phenotype and activates the Notch pathway in MTC-TT cell line.
Tesfazghi S; Eide J; Dammalapati A; Korlesky C; Wyche TP; Bugni TS; Chen H; Jaskula-Sztul R
Cancer Med; 2013 Oct; 2(5):734-43. PubMed ID: 24403239
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.
Koh YW; Shah MH; Agarwal K; McCarty SK; Koo BS; Brendel VJ; Wang C; Porter K; Jarjoura D; Saji M; Ringel MD
Endocr Relat Cancer; 2012 Feb; 19(1):29-38. PubMed ID: 22109971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
